Prediction: 2 Stocks That Will Be Worth More Than SoundHound AI 2 Years From Now

SoundHound AI reported robust Q2 2025 revenue growth of 217% to $42.7 million, driven by AI voice offerings, and raised its 2025 guidance, with its market cap projected to reach $9.4 billion by 2027. However, CRISPR Therapeutics, with its commercialized gene-editing therapy Casgevy and a strong cardiovascular pipeline, and Semtech, benefiting from surging data center and AI infrastructure demand, significant debt reduction, and improved profitability, are positioned for substantial growth that could enable them to exceed SoundHound AI's market valuation within the same timeframe.

Analysis

SoundHound AI demonstrated robust growth in Q2 2025, with revenue soaring 217% year-over-year to $42.7 million, driven by strong adoption of its AI-powered voice offerings across automotive, restaurant, and enterprise sectors. The company also raised its 2025 revenue guidance to a range of $160 million to $178 million, reflecting sustained business momentum. While its market capitalization is projected to reach $9.4 billion by 2027, this forecast relies on a price-to-sales multiple reverting to historical averages.

CRISPR Therapeutics, a prominent gene-editing firm, presents a compelling growth narrative, with its shares up 63% in 2025 and a current market capitalization of $5.84 billion. The company has successfully commercialized Casgevy for sickle cell disease, with 75+ treatment centers activated and rising patient referrals, targeting a multibillion-dollar market opportunity. Additionally, its robust cardiovascular pipeline, including CTX310 and CTX320, holds significant long-term potential, supported by $1.7 billion in cash for continued R&D and commercial rollout.

Semtech, a designer of high-performance chips, has significantly improved its financial health, reducing debt by $879 million and lowering interest expense by 80% year-over-year in Q2 FY26, with its net leverage ratio improving from 8.8 to 1.6. The data center business is a key growth driver, with revenue up 92% year-over-year to $52.2 million, fueled by hyperscaler adoption of its FiberEdge and CopperEdge products for network upgrades. The company's overall Q2 revenue grew 20% to $257.6 million, accompanied by margin expansion and a shift to positive free cash flow of $41.5 million, positioning it for continued market cap appreciation.

Key Decisions for Investors

• Investors should closely monitor SoundHound AI's actual revenue growth against its raised 2025 guidance and the sustainability of its elevated price-to-sales multiple for long-term valuation.
• For CRISPR Therapeutics, focus on the commercial ramp-up of Casgevy and clinical trial progress of its cardiovascular pipeline, particularly any major pharmaceutical partnership announcements.
• Track Semtech's continued debt reduction, margin expansion, and the adoption rate of its data center and AI infrastructure solutions, as these are key drivers for its market capitalization growth.
• Given the strong growth prospects across all three companies, investors may consider a diversified approach or conduct deeper due diligence on each company's specific catalysts and risk factors.